Diffusion of naltrexone across reconstituted human oral epithelium and histomorphological features

被引:41
作者
Giannola, Libero Italo
De Caro, Viviana
Giandalia, Giulia
Siragusa, Maria Gabriella
Campisi, Giuseppina
Florena, Ada Maria
Ciach, Tomasz
机构
[1] Univ Palermo, Dipartimento Chim & Tecnol Farmaceut, I-90123 Palermo, Italy
[2] Univ Palermo, Dipartimento Sci Stomatol, I-90133 Palermo, Italy
[3] Univ Palermo, Ist Anat & Istol Patol, I-90133 Palermo, Italy
[4] Warsaw Univ Technol, Fac Chem & Proc Engn, PL-00661 Warsaw, Poland
关键词
buccal permeation; transbuccal absorption; naltrexone hydrochloride; reconstituted human oral epithelium (RHO); iontophoresis; penetration enhancers;
D O I
10.1016/j.ejpb.2006.07.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In transbuccal absorption a major limitation could be the low permeability of the mucosa which implies low drug bioavailability. The ability of naltrexone hydrochloride (NLX) to penetrate a resembling histologically human buccal mucosa was assessed and the occurrence of any histomorphological changes observed. We used reconstituted human oral (RHO) non-keratinised epithelium as mucosal section and a Transwell diffusion cells system as bicompartmental model. Buccal permeation was expressed in terms of drug flux (J(s)) and permeability coefficients (K-p). Data were collected using both artificial and natural human saliva. The main finding was that RHO does not restrain NLX permeation. Drug transport across the epithelium was observed also in presence of various concentrations of penetration enhancers, without any significant differences. On the contrary, the flux throughout the mucosa was extensively affected by iontophoresis. Histologically, no sign of flogosis was observed in any specimen under experiment without iontophoresis, whereas cytoarchitectural changes, up to nuclear pycnosis or cellular swelling, were determined as a consequence of the application of electric fields. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:238 / 246
页数:9
相关论文
共 24 条
[1]   Transbuccal permeation, anti-inflammatory activity and clinical efficacy of piroxicam formulated in different gels [J].
Attia, MA ;
El-Gibaly, I ;
Shaltout, SE ;
Fetih, GN .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 276 (1-2) :11-28
[2]   Depot naltrexone: long-lasting antagonism of the effects of heroin in humans [J].
Comer, SD ;
Collins, ED ;
Kleber, HD ;
Nuwayser, ES ;
Kerrigan, JH ;
Fischman, MW .
PSYCHOPHARMACOLOGY, 2002, 159 (04) :351-360
[3]   About a synthetic saliva for in vitro studies [J].
Gal, JY ;
Fovet, Y ;
Adib-Yadzi, M .
TALANTA, 2001, 53 (06) :1103-1115
[4]  
Giannola L I, 2005, Int J Immunopathol Pharmacol, V18, P21
[5]   Buccal delivery systems [J].
Hao, JS ;
Heng, PWS .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2003, 29 (08) :821-832
[6]   TR146 CELLS GROWN ON FILTERS AS A MODEL FOR HUMAN BUCCAL EPITHELIUM .1. MORPHOLOGY, GROWTH, BARRIER PROPERTIES, AND PERMEABILITY [J].
JACOBSEN, J ;
VANDEURS, B ;
PEDERSEN, M ;
RASSING, MR .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1995, 125 (02) :165-184
[7]   Buccal iontophoretic delivery of atenolol•HCl employing a new in vitro three-chamber permeation cell [J].
Jacobsen, J .
JOURNAL OF CONTROLLED RELEASE, 2001, 70 (1-2) :83-95
[8]   Iontophoretic drug delivery [J].
Kalia, YN ;
Naik, A ;
Garrison, J ;
Guy, RH .
ADVANCED DRUG DELIVERY REVIEWS, 2004, 56 (05) :619-658
[9]  
KAUFMANN JJ, 1975, J MED CHEM, V14, P647
[10]   Mechanistic model for transdermal transport including iontophoresis [J].
Kontturi, K ;
Murtomaki, L .
JOURNAL OF CONTROLLED RELEASE, 1996, 41 (03) :177-185